BRAIN Biotech AG
General | General InformationGeneral Information
| Company name | BRAIN Biotech AG |
|
| Company website | www.brain-biotech-group.com | |
| Number of employees | 250 - 499 | |
| Reporting year | 2021 | |
| Indicator set | GRI SRS | |
| Directly affected by the disclosure of non-financial and diversity information | No | |
| Reporting on EU taxonomy | not subject to the reporting obligation and not reporting according to EU taxonomy | |
| Contact |
BRAIN Biotech AG
Associate Manager ESG & Sustainability Almut Kohl Darmstädter Straße 34-36 64673 Zwingenberg Germany +49-6251-9331-0 alk@brain-biotech.com |
|
Describe your business model (including type of company, products / services)
BRAIN Biotech AG is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group.
Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the incubator we develop breakthrough products and services with significant economic potential and positive environmental impact. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Continental-Europe, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group. In the fiscal year 2020/21 BRAIN Biotech AG generated a turnover of EUR 38.4 million with an adj. EBITDA loss of EUR 2.5 million. While our underlying business segments BioScience and BioIndustrial are both profitable we continue to invest more into our incubator pipeline, our future growth and value driver, when we currently generate on our operating business. It is our clear intention to turn profitable on a group level within the next years. We have announced ambitious mid-term targets at our Capital Markets Day in September, 2020, to double our revenues and reach a mid-point EBITDA margin of 15%.[1] Since the IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the incubator we develop breakthrough products and services with significant economic potential and positive environmental impact. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Continental-Europe, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group. In the fiscal year 2020/21 BRAIN Biotech AG generated a turnover of EUR 38.4 million with an adj. EBITDA loss of EUR 2.5 million. While our underlying business segments BioScience and BioIndustrial are both profitable we continue to invest more into our incubator pipeline, our future growth and value driver, when we currently generate on our operating business. It is our clear intention to turn profitable on a group level within the next years. We have announced ambitious mid-term targets at our Capital Markets Day in September, 2020, to double our revenues and reach a mid-point EBITDA margin of 15%.[1] Since the IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Additional remarks:
BRAINimpact
Already today we directly address at least five of the UN Sustainability Development Goals by our products and services. We really can make a difference with solutions for the SDGs 2, 3, 6, 9 and 12. Most of our impact services and products are developed within our incubator pipeline. In our incubator we currently have eleven programs at different stages of maturity. All of them address big societal topics in the areas of nutrition, health and environment. By this our products and services directly contribute to a more sustainable lifestyle, better health, the preservation of primary resources and, with our genome engineering platform, offer a basis technology also applicable to the important biologization of industrial processes.
Already today we directly address at least five of the UN Sustainability Development Goals by our products and services. We really can make a difference with solutions for the SDGs 2, 3, 6, 9 and 12. Most of our impact services and products are developed within our incubator pipeline. In our incubator we currently have eleven programs at different stages of maturity. All of them address big societal topics in the areas of nutrition, health and environment. By this our products and services directly contribute to a more sustainable lifestyle, better health, the preservation of primary resources and, with our genome engineering platform, offer a basis technology also applicable to the important biologization of industrial processes.